Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Other 1NET 1Gastrointestinal 1CNS 1

Conditions

Hypoglycemia 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

lutetium Lu 177 dotatate 32Everolimus 19Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 12Temozolomide 12Nivolumab 11Capecitabine 10pembrolizumab 9lanreotide 9cabozantinib 8Positron Emission Tomography Computed Tomography 8177Lu-octreotide, DOTA(0)-Tyr(3)- 8Ga(III)-DOTATOC 73-Iodobenzylguanidine 7Somatostatin 6Octreotide 6Lutetium-177 6Carboplatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5surufatinib 5lenvatinib 5Ipilimumab 5Fluorodeoxyglucose F18 5pasireotide 4copper dotatate CU-64 4avelumab 4Single Photon Emission Computed Tomography Computed Tomography 4Positron-Emission Tomography 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Diazoxide × NET × Clear all
NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡